# Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

> **NCT03575234** · PHASE1 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma
- Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

## Interventions

- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** IRX-2
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT03575234
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-01
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-01-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** funding and drug were withdrawn
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03575234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03575234, "Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03575234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*